Davis Polk advised underwriters represented by Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and RBS Securities Inc. in connection with the offering of $4 billion aggregate principal amount of notes issued by Pfizer Inc. The notes were offered in five tranches, one floating-rate tranche maturing in 2018 and four fixed-rate tranches maturing in 2017, 2018, 2023 and 2043.
Pfizer is a research-based global pharmaceutical company. Pfizer’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer health care products.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Christopher R. Bornhorst and Rashna Bhojwani. The tax team included partner Samuel Dimon and associate Craig A. Phillips. The environmental team included counsel Betty Moy Huber and law clerk Michael Comstock. The intellectual property team included associate David R. Bauer and law clerk Natalie A. Thomas. Sorina Delia Lazar was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
